BioStem Signs LOI to Acquire ProgenaCare's Wound Care Products
Deal News | Nov 20, 2024 | Globenewswire
BioStem Technologies Inc., a MedTech company specializing in placental-derived biologics, has signed a Letter of Intent to acquire wound care products and technologies from ProgenaCare Global LLC. The acquisition will include commercial-stage products such as ProgenaMatrix and revyve Antimicrobial Wound Gel, with the aim of expanding BioStem's wound care product portfolio. The transaction is pending regulatory approvals and is expected to be finalized in 60 days. ProgenaCare’s technologies will enhance BioStem’s capacity to support a broader range of wound care solutions. Both companies expect operational synergies from this partnership, especially in product development and market reach. The move aligns with BioStem's strategic initiatives to provide comprehensive wound care solutions and leverage its commercial infrastructure.
Sectors
- Medical Technology
- Biologics
- Wound Care
Geography
- United States – BioStem Technologies is located in Pompano Beach, Florida, and the transaction and company operations are based in the U.S.
Industry
- Medical Technology – The article discusses BioStem Technologies' focus on the development and commercialization of medical products, such as allografts, used in regenerative medicine.
- Biologics – BioStem is involved in the manufacture of biologic products, leveraging its proprietary BioREtain processing method to develop placental allografts.
- Wound Care – ProgenaCare’s product portfolio, including ProgenaMatrix and revyve, falls under wound care technologies, addressing various wound types and conditions.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| BioStem Technologies Inc. | Bidding Company | Company | A MedTech company specializing in placental-derived biologics and regenerative therapies. |
| ProgenaCare Global LLC | Target Company | Company | A medical device company offering advanced wound care solutions through biomaterials. |
| Jason Matuszewski | CEO of BioStem | Person | Chief Executive Officer of BioStem Technologies. |
| Howard Wathall | CEO of ProgenaCare | Person | Chief Executive Officer of ProgenaCare Global. |
| PCG Advisory | Investor Relations | Company | Provides investor relations services as mentioned in the contact section. |